To date, promising results in terms of objective tumor response have been observed with tanespimycin in combination with trastuzumab in patients progressing on trastuzumab (NCT00773344) [32] and more recently with single-agent ganetespib in trastuzumab-refractory HER2-positive tumors and TNBC (NCT01677455) [33]. Here, ERBB2 is linked to neoplasm.